Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIANGLE / HOVON 133 in untreated younger mantle cell lymphoma
NL-OMON55612Phase 3Recruiting
- Sponsor
- LMU Klinikum
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Failure-free survival. Started Nov 2017; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON55612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55612.